Novoste CEO’s Challenge: Stabilize Brachy Biz Or Ink Merger While Cash Lasts

Novoste's cash burn rate of about $1 mil. per month puts pressure on management either to acquire a growth platform to augment flagging Beta-Cath vascular brachytherapy revenue or sell the company